| 2024 | Volume |
| Changes to Thyroseq Molecular Thyroid Test | 4 |
| Glucose-6-Phosphate Dehydrogenase | 3 |
| Body Fluid Lower Reportable Cell Count Ranges | 2 |
| Requirement changes for 24-hour Urine Preservative | 1 |
| 2023 | Volume |
| Munson Medical Center Immature Granulocyte (IG) Reporting | 14 |
| Collection and Instrument Updated Roche CTGC and TVDNA | 13 |
| Changes to Clostridioides Difficile Testing | 12 |
| Tick Borne Pathogens Anaplasma | 11 |
| Munson Medical Center Lab Hematology Testing Transitioning to New Platform | 10 |
| MHC Standardizing Lab Critical Values | 9 |
| Rhlg from Ortho Rhogam to CSL Behring Rhophylac | 8 |
| Collection Changes for and Instrument changes for Chlamydia trachomatis Neisseria gonorrhoeae and Trichomonas vaginalis | 7 |
| Chemistry Automation Line – Specimen Stability | 6 |
| eGFR Calculations | 5 |
| Infectious Vaginitis Testing | 4 |
| Changes to Urine Drug of Abuse Screen Testing | 3 |
| Heparin-Induced Thrombocytonpenia (HIT) Testing | 2 |
| D-dimer Reporting | 1 |
| 2022 | Volume |
| Discontinuation of Direct Bilirubin and Total Bilirubin Reflex Test | 6 |
| Michigan Lyme Disease Testing | 5 |
| GI (Diarrhea) Testing Panel Update | 4 |
| Stago Coagulation Analyzers -- Cadillac Hospital | 3 |
| Biofire Bacterial Pathogen Resistance Gene Testing | 2 |
| Group A Strep Test Communication | 1 |
| 2021 | Volume |
| Electronic Crossmatch and ABO Verification and History Check | 16 |
| Respiratory Syncytial Virus (RSV) | 15 |
| Stago Coagulation Analyzers | 14 |
| Respiratory testing for 2021-2022 | 13 |
| Specimen Rejection Policy – Clinical Laboratory Specimens | 12 |
| Billing and Coding: Foodborne Gastrointestinal Panels Identified by Multiplex Nucleic Acid Amplification | GI Reimbursement Memo | 11 |
| Submitting specimens for laboratory testing | 10 |
| Increased range of results for reporting urinalysis chemistry analytes | 9 |
| Serum and Urine: Immunoglobulin, Complement, Immunofixation, Free Light Chain and Electrophoresis, testing to Mayo | 8 |
| ABO Verification and History Check | 7 |
| Urine specimens for Chlamydia, Gonorrhea, & Trichomonas | 6 |
| COVIDP GIP CTGC and CRYO Updates | 5 |
| Gastrointestinal Pathogen PCR Panel | 4 |
| The Paris System for Reporting Urine Cytology | 3 |
| Influenza and RSV Testing | 2 |
| Group A Strep Test Communication | 1 |
| 2020 | Volume |
| EV replacement Urine for CTGC Group A strep testing | 8 |
| Gonorrhea and Chlamydia Samples | 7 |
| Immunology Testing | 6 |
| Chlamydia, Neisseria, Trichomonas Testing | 5 |
| Reporting of Magnesium Results | 4 |
| Pertussis and Lyme Disease | 3 |
| Reporting of Magnesium Results | 2 |
| Microbiology Changes | 1 |
| 2019 | Volume |
| Policy regarding Skin Specimen for Frozen Sections | 5 |
| Helicobacter Pylori Stool Antigen Testing | 4 |
| VerifyNow Testing Platform | 3 |
| Measles | 2 |
| Removal of the test "Reducing Substances, Urine" | Removal of the test "Magnesium, Red Blood Cell" | 1 |
| 2018 | Volume |
| Fluoroquinolones | 4 |
| Kappa and Lambda Immunoglobulin Free Light Chain Testing | 3 |
| Clostridium Difficile Testing | 2 |
| p02 and pC02 Discontinued Tests | 1 |
| 2017 | Volume |
| Immunoassays at MMC II | 11 |
| Troponins New Reference Range | 10 |
| Clostridium Difficile Testing | 9 |
| Immunoassays at MMC | 8 |
| Hepatitis C Screening Test Now Available | 7 |
| Helicobacter Pylori Testing | 6 |
| Plasma | 5 |
| Absolute Neutrophil Count (ANC) | 4 |
| Urine Culture | 3 |
| Post-Vasectomy Semen Analysis (PVSA) | 2 |
| Upgraded Assay for Thyroid Function Cascade and TSH Testing | 1 |